红日药业
(300026)
| 流通市值：93.47亿 | | | 总市值：104.54亿 |
| 流通股本：26.86亿 | | | 总股本：30.04亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,441,070,030.88 | 2,996,233,822.37 | 1,463,378,271.09 | 6,108,854,649.13 |
| 营业收入 | 4,441,070,030.88 | 2,996,233,822.37 | 1,463,378,271.09 | 6,108,854,649.13 |
| 二、营业总成本 | 4,202,854,621.74 | 2,804,625,482.18 | 1,367,139,489.84 | 5,588,556,579.05 |
| 营业成本 | 2,122,686,471.76 | 1,409,843,503.15 | 713,224,029.44 | 2,803,386,934.52 |
| 税金及附加 | 45,538,357.41 | 32,842,118.68 | 15,548,221.38 | 57,844,376.89 |
| 销售费用 | 1,546,879,956.41 | 1,044,589,975.05 | 478,574,064.57 | 2,027,793,606.02 |
| 管理费用 | 305,516,540.8 | 204,157,808.74 | 105,080,287.27 | 438,239,370.18 |
| 研发费用 | 154,099,892.09 | 93,690,072.63 | 44,359,218.24 | 215,586,573.83 |
| 财务费用 | 28,133,403.27 | 19,502,003.93 | 10,353,668.94 | 45,705,717.61 |
| 其中:利息费用 | 40,122,503.31 | 28,579,800.37 | 15,211,795.6 | 61,573,799.47 |
| 其中:利息收入 | 13,730,032.52 | 9,607,655.88 | 5,535,769.7 | 19,311,266.92 |
| 加:投资收益 | -1,101,399.18 | -1,233,781.77 | -245,327.99 | -1,401,143.81 |
| 资产处置收益 | -63,974.29 | 574,690.39 | 3,127.92 | 1,062,744.31 |
| 资产减值损失(新) | -11,779,924.04 | -6,346,246.7 | -2,267,930.03 | -37,632,129.5 |
| 信用减值损失(新) | -50,473,991.06 | -37,945,894.39 | -25,030,896.15 | -65,488,916.13 |
| 其他收益 | 26,330,754.4 | 17,655,123.81 | 7,302,176.42 | 72,426,594.88 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 201,126,874.97 | 164,312,231.53 | 75,999,931.42 | 489,265,219.83 |
| 加:营业外收入 | 12,257,304.99 | 10,717,586.82 | 1,204,232.84 | 125,812,030.36 |
| 减:营业外支出 | 11,467,516.86 | 5,132,653.68 | 269,471.4 | 8,254,177.32 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 201,916,663.1 | 169,897,164.67 | 76,934,692.86 | 606,823,072.87 |
| 减:所得税费用 | 9,518,747.51 | 17,283,566.7 | 22,536,584.18 | 105,254,814.91 |
| 六、净利润 | 192,397,915.59 | 152,613,597.97 | 54,398,108.68 | 501,568,257.96 |
| 持续经营净利润 | 192,397,915.59 | 152,613,597.97 | 54,398,108.68 | 501,568,257.96 |
| 归属于母公司股东的净利润 | 168,356,759.92 | 148,232,272.9 | 58,120,874.65 | 506,631,425.7 |
| 少数股东损益 | 24,041,155.67 | 4,381,325.07 | -3,722,765.97 | -5,063,167.74 |
| (一)基本每股收益 | 0.06 | 0.05 | 0.02 | 0.17 |
| (二)稀释每股收益 | 0.06 | 0.05 | 0.02 | 0.17 |
| 八、其他综合收益 | -1,508,970.79 | 821,465.12 | -422,152.76 | 3,894,451.92 |
| 归属于母公司股东的其他综合收益 | -1,508,970.79 | 821,465.12 | -422,152.76 | 3,894,451.92 |
| 九、综合收益总额 | 190,888,944.8 | 153,435,063.09 | 53,975,955.92 | 505,462,709.88 |
| 归属于母公司股东的综合收益总额 | 166,847,789.13 | 149,053,738.02 | 57,698,721.89 | 510,525,877.62 |
| 归属于少数股东的综合收益总额 | 24,041,155.67 | 4,381,325.07 | -3,722,765.97 | -5,063,167.74 |
| 公告日期 | 2024-10-25 | 2024-08-30 | 2024-04-26 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |